Epidemiology

Analysis Group Announces Senior-Level Promotions

Retrieved on: 
Thursday, April 4, 2024
HTA, Consumer, Climate change, Bankruptcy, Algorithm, ERISA, Environment, Agriculture, Data analysis, RWE, Materiality, Biostatistics, Research, History, Policy, Epidemiology, Survival analysis, Insurance, Analysis Group, Advertising, Clinical trial, IP, Ground substance, Intellectual property, Telecommunications, Privacy, Marketing, Economics, Consultant

BOSTON, April 4, 2024 /PRNewswire/ -- Analysis Group , one of the largest international economics consulting firms, announces 32 promotions to vice president across nine offices.

Key Points: 
  • BOSTON, April 4, 2024 /PRNewswire/ -- Analysis Group , one of the largest international economics consulting firms, announces 32 promotions to vice president across nine offices.
  • "We are delighted to announce the largest group of consultant promotions to vice president in the history of our organization," said Martha S. Samuelson, CEO and Chairman of Analysis Group.
  • In Boston, Jonathan E. Baker specializes in the application of economic analysis to antitrust and competition, energy and environment, commercial dispute, class certification, and damages litigation matters.
  • Erica VanSant specializes in economic analysis of complex litigation matters in the areas of health care, antitrust, and IP.

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

Retrieved on: 
Thursday, March 28, 2024
B-cell lymphoma, Plasma, Shanghai Cancer Center, Rituximab, Apoptosis, Leukemia, International Journal of Hematology, Patient, Hospital, Doxorubicin, Vincristine, Fudan University, CC3, Standard of care, Acute myeloid leukemia, Epidemiology, Biomedical Chromatography, Prednisone, Peripheral T-cell lymphoma, PARP, National Cancer Center, Therapy, MYC, BTK, Safety, BeiGene, CDK9, Cyclophosphamide, DLBCL, Canadian International Council, MCL1, Follicular lymphoma, Pharmaceutical industry

The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.

Key Points: 
  • The first patient was dosed in the trial led by prominent Henan Cancer Hospital and Fudan University Shanghai Cancer Center.
  • This study will be the first combination trial conducted by a Chinese biotech to combine CDK9 inhibitor and BTK inhibitor targeting DLBCL.
  • The trials of GFH009 treating peripheral T-cell lymphoma and acute myeloid leukemia have entered into phase II stage in China and the U.S. respectively.
  • Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025, Leukemia & Lymphoma, 2021
    3.

Environmental Risk and Compliance Strategy Expert Tapped for Leadership at J.S. Held

Retrieved on: 
Wednesday, March 13, 2024
Health, EH&S, Forward, Risk, Suspension, Environment, Biophysical environment, Pass, ESG, EH, Epidemiology, EPA, Fossil fuel, Safety, Toxicology, Superfund, Crosscurrents, EHS, Management

Held, proudly celebrating 50 transformative years, elevates Executive Vice President John Peiserich, Esq ., to oversee the Environmental, Health & Safety (EHS) practice.

Key Points: 
  • Held, proudly celebrating 50 transformative years, elevates Executive Vice President John Peiserich, Esq ., to oversee the Environmental, Health & Safety (EHS) practice.
  • Held environmental risk and compliance strategy experts, John holds a J.D.
  • "John's background as a practicing environmental attorney best positions John to understand, anticipate, and discuss with counsel the ever-changing legal landscape surrounding environmental risk and compliance strategy," observes Paul Banks.
  • John has extensive experience evaluating the risk associated with potential and ongoing compliance obligations, developing strategies around those obligations, and working to implement a client-focused compliance strategy.

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024

Retrieved on: 
Thursday, March 7, 2024
EDT, Master of Science, MD, Diabetic neuropathy, Notalgia paresthetica, FRCPC, Therapy, Webcast, Patient, Diagnosis, Itch, Epidemiology, KOL

The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology, diagnosis, treatment landscape, and significant unmet medical need in notalgia paresthetica (NP).

Key Points: 
  • The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology, diagnosis, treatment landscape, and significant unmet medical need in notalgia paresthetica (NP).
  • The live panel discussion will be moderated by Joana Goncalves, MD, Chief Medical Officer of Cara Therapeutics.
  • The event will also highlight oral difelikefalin in NP and its potential in this underserved neuropathy.
  • A live webcast of the event will be accessible under “Events & Presentations” in the Investors section of the Company’s website at www.CaraTherapeutics.com .

Novotech Publishes Duchenne Muscular Dystrophy Landscape Report to Support Biotech Research Planning

Retrieved on: 
Wednesday, February 28, 2024
Therapy, Genetic disorder, Investment, Clinical trial, DMD, SWOT, Duchenne muscular dystrophy, Muscular dystrophy, Prevalence, Contract research organization, RNA, Organization, Disease, Diagnosis, Male, Mutation, ROW, Epidemiology, Research, Pharmaceutical industry

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novotech , the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released today an industry-leading report on Duchenne Muscular Dystrophy (DMD) Clinical Trial Landscape .

Key Points: 
  • BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novotech , the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released today an industry-leading report on Duchenne Muscular Dystrophy (DMD) Clinical Trial Landscape .
  • The Novotech research analyst team provides these expert reports monthly, completely free of charge.
  • They tackle the hurdles faced by biotech firms in specific therapeutic areas and discuss future paths in therapy and investment trends.
  • This comprehensive resource guides healthcare professionals, researchers, and organizations in navigating the complex clinical trial DMD landscape.

Inflammatory Bowel Disease Expert and Harvard Medical School Faculty Dr. Hamed Khalili Joins Vivante Health’s Clinical Advisory Board

Retrieved on: 
Monday, February 26, 2024
Research, American Gastroenterological Association, Inflammatory Bowel Diseases, Education, Colorectal cancer, Physician, Quality of life, Hospital, Epidemiology, Gastrointestinal cancer, Vivante Corporation, American College, Inflammatory bowel disease, Associate, Massachusetts General Hospital, Harvard Medical School, Stanford University Medical Center, State, Nursing

CHICAGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, announced the addition of Dr. Hamed Khalili to its Clinical Advisory Board today.

Key Points: 
  • CHICAGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, announced the addition of Dr. Hamed Khalili to its Clinical Advisory Board today.
  • Dr. Khalili is a gastroenterologist and Director of Clinical Research at Massachusetts General Hospital, Crohn’s and Colitis Center and an Associate Professor at Harvard Medical School.
  • His research focuses on studying dietary and lifestyle factors and their relationship to the development and progression of inflammatory bowel diseases.
  • “Vivante Health is doing fantastic work to care for people with digestive conditions, particularly in the area of inflammatory bowel disease and other digestive conditions.

Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts

Retrieved on: 
Thursday, February 22, 2024
Allotransplantation, Skin cancer, Cholangiocarcinoma, Fast track (FDA), NHL, Melanoma, FDA, Pembrolizumab, CD19, Rupture, Lung, Epidemiology, Breast, Safety, Neoplasm, ASX, Bone marrow, Patient, RECIST, MAST, National library, IMU, Blinatumomab, DLBCL, Cancer, BTC, Vaccine

Imugene Managing Director & CEO Leslie Chong said: “We are encouraged by the initial safety and efficacy signals seen to date.

Key Points: 
  • Imugene Managing Director & CEO Leslie Chong said: “We are encouraged by the initial safety and efficacy signals seen to date.
  • Notably, in our Phase 1 MAST CF33 oncolytic virus trial, we’ve seen encouraging response rates during dose escalation, including one complete response in a patient with cholangiocarcinoma, and two partial responses in melanoma as we continue to dose escalate with no safety issues.
  • Importantly, two out of three of these responses were achieved with CF33 monotherapy.
  • onCARlytics uses an antigen/target-armed CF33, followed by treatment with a CD19 targeting therapy directed against that antigen or target.

Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 with Focus on 7 Major Markets - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024
Pharmaceutical, Health, Clinical Trials, Therapy, Key, Inflation, Competitive landscape, Physician, News, Opinion, SWOT, EU4, AIS, Safety, HTA, Patient, Clinical trial, Disease, Enzyme inhibitor, Drug, Mutation, Epidemiology, Pharmaceutical industry

The "Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Aromatase Inhibitors (AIs) market report provides insights around existing treatment practices in patients with Aromatase Inhibitors (AIs), approved (if any) and emerging Aromatase Inhibitors (AIs), market share of individual therapies, patient pool eligible for treatment with Aromatase Inhibitors (AIs), along with current and forecasted 7MM Aromatase Inhibitors (AIs) market size from 2020-2034 by therapies and by indication.
  • Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications.
  • This section will include details on changing Aromatase Inhibitors (AIs) market dynamics post initiation of clinical development activities of the inhibitor.

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Wednesday, February 28, 2024
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Well, Neoplasm, Psoriasis, DecisionDx-UM, Investment, News, Growth, Table, Uveal melanoma, Epidemiology, SCC, Webcast, Diagnosis, Mortality, Woman, Melanoma, Cohort (statistics), Recurrence, BWH, Overalls, Radiation, Metastasis, Mycosis fungoides, GAAP, Journal, Net, Depreciation, PSO, Major depressive disorder, Randomized controlled trial, Atopic dermatitis, Adjustment, Practitioner, ART, Castle, National Comprehensive Cancer Network, Survival, MDD, Workflow, Acquisition, MF, Risk, Medicare, NCCN, Patient, Pharmaceutical industry

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.
  • DecisionDx-SCC test reports delivered in the quarter were 3,530, compared to 1,845 in the fourth quarter of 2022, an increase of 91%.
  • DecisionDx-UM test reports delivered in the quarter were 405, compared to 432 in the fourth quarter of 2022, a decrease of 6%.
  • Castle Biosciences will hold a conference call on Wednesday, Feb. 28, 2024, at 4:30 p.m. Eastern time to discuss its fourth quarter and full-year 2023 results and provide a corporate update.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, General Health, Pharmaceutical, Health, Therapy, Inflation, Competitive landscape, PCSK9, Proprotein convertase, Physician, News, SWOT, EU4, Safety, HTA, Patient, Disease, Drug, Mutation, Epidemiology, Pharmaceutical industry

The "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors market report provides insights around existing treatment practices in patients with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, approved (if any) and emerging Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, market share of individual therapies, patient pool eligible for treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, along with current and forecasted 7MM Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors market size from 2020-2034 by therapies and by indication.
  • The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors marketed drug section will provide detailed drug profiles of already approved therapies.
  • The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.